Opaleye Management Inc.'s Form 4 filing
Eton Pharmaceuticals, Inc. (ETON) · filed Jul 16, 2026
- Accession no.
- 0001493152-26-033577
- Filed
- Jul 16, 2026, 5:14 PM ET
- Trade date
- Jul 14, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.06M. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001493152-26-033818 (Jul 17, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Common Stock, par value $0.001 per share | SSaleDisposed | −15,000 | $37.54F3 | −$563,146.5 | 2,665,000 | Indirect | |
| Jul 14, 2026 | Common Stock, par value $0.001 per share | SSaleDisposed | −13,315 | $37.54F3 | −$499,886.38 | 40,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0152 to $37.9148 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
Referenced by the price of 2 transactions in Table I.